Effect of evolocumab on the levels of blood lipids,MHR and NLR in ACS patients after percutaneous coronary intervention
10.3969/j.issn.1008-0074.2025.02.20
- VernacularTitle:依洛尤单抗对ACS患者PCI术后血脂、MHR、NLR的影响
- Author:
Li-yuan WEI
1
;
Shan JIANG
1
Author Information
1. 锦州市中心医院心血管内科,辽宁锦州 121000
- Publication Type:Journal Article
- Keywords:
Acute Coronary Syndrome;
Angioplasty,balloon,coronary;
Evolocumab
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2025;34(2):236-241
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the effect of evolocumab on the levels of blood lipids,monocyte-to-high density lipo-protein cholesterol ratio(MHR)and neutrophil-to-lymphocyte ratio(NLR)in patients with acute coronary syndrome(ACS)after percutaneous coronary intervention(PCI).Methods:We enrolled 112 ACS patients who underwent PCI in Jinzhou Central Hospital between December 2021 and September 2023.According to medication,the patients were divided into control group(n=60,atorvastatin therapy)and combined treatment group(n=52,atorvastatin combined with evo-locumab therapy),both groups were treated for 3 months.Blood lipids,inflammatory factors,MHR and NLR were com-pared between two groups.Results:Compared with patients in control group after treatment,those in combined treatment group had significant lower total cholesterol(TC)[(3.29±0.78)mmol/L vs.(3.69±0.85)mmol/L],low density lipo-protein cholesterol(LDL-C)[(1.24±0.40)mmol/L vs.(1.79±0.52)mmol/L],apolipoprotein B(ApoB)[(73.46±16.21)mg/ml vs.(93.02±17.13)mg/ml],high sensitive C-reactive protein(hsCRP)[(2.16±0.77)mg/L vs.(2.53±0.89)mg/L]and MHR[(0.25±0.07)×109/mmolvs.(0.30±0.09)× 109/mmol](P＜0.05 or＜0.01).Conclusion:Evolocumab combined with atorvastatin possesses a significant regulating effecton monocyte-to-highdensity lipoprotein cholesterol ratio and blood lipids,and significantly reduces inflammatory factor levels in patients with acute cor-onary syndrome after percutaneous coronary intervention.
